Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Probiotic helps treat diabetes in rats, could lead to human remedy

30.01.2015

Science may be one step closer to treating diabetes with a human probiotic pill, according to new Cornell University research.

In the study, published Jan. 27 in the journal Diabetes, the researchers engineered a strain of lactobacillus, a human probiotic common in the gut, to secrete a Glucagon-like peptide 1 (GLP-1). They then administered it orally to diabetic rats for 90 days and found the rats receiving the engineered probiotic had up to 30 percent lower high blood glucose, a hallmark of diabetes.


This is an image showing a rat cell re-programmed to express HNF-6 (red) and insulin (green). The nucleus is stained blue. Re-printed with permission from Diabetes.

Credit: Re-printed with permission from Diabetes. Cornell University

The study was a proof of principle, and future work will test higher doses to see if a complete treatment can be achieved, said John March, professor of biological and environmental engineering at Cornell University and the paper's senior author.

The researchers found that upper intestinal epithelial cells in diabetic rats were converted into cells that acted very much like pancreatic beta cells, which monitor blood glucose levels and secrete insulin as needed to balance glucose levels in healthy individuals.

"The amount of time to reduce glucose levels following a meal is the same as in a normal rat, ... and it is matched to the amount of glucose in the blood," just as it would be with a normal-functioning pancreas, March said. "It's moving the center of glucose control from the pancreas to the upper intestine."

Also, though it replaces the insulin capacity in diabetic rats, the researchers found no change in blood glucose levels when administered to healthy rats. "If the rat is managing its glucose, it doesn't need more insulin," March said.

This technology was licensed by the BioPancreate, a wholly-owned subsidiary of Cortendo AB, a biopharmaceutical company incorporated in Sweden and based in Radnor, Penn., which is working to get the therapy into production for human use.

Human patients would likely take a pill each morning to help control their diabetes, March said.

###

The study is funded by the National Institutes of Health and the Hartwell Foundation.

Cornell University has television, ISDN and dedicated Skype/Google+ Hangout studios available for media interviews.

Media Contact

Melissa Osgood
mmo59@cornell.edu
607-255-2059

 @cornell

http://pressoffice.cornell.edu 

Melissa Osgood | EurekAlert!

More articles from Life Sciences:

nachricht Immune Defense Without Collateral Damage
23.01.2017 | Universität Basel

nachricht The interactome of infected neural cells reveals new therapeutic targets for Zika
23.01.2017 | D'Or Institute for Research and Education

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Quantum optical sensor for the first time tested in space – with a laser system from Berlin

For the first time ever, a cloud of ultra-cold atoms has been successfully created in space on board of a sounding rocket. The MAIUS mission demonstrates that quantum optical sensors can be operated even in harsh environments like space – a prerequi-site for finding answers to the most challenging questions of fundamental physics and an important innovation driver for everyday applications.

According to Albert Einstein's Equivalence Principle, all bodies are accelerated at the same rate by the Earth's gravity, regardless of their properties. This...

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

Tracking movement of immune cells identifies key first steps in inflammatory arthritis

23.01.2017 | Health and Medicine

Electrocatalysis can advance green transition

23.01.2017 | Physics and Astronomy

New technology for mass-production of complex molded composite components

23.01.2017 | Process Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>